Comparison of Culture- and Non-Culture-Based Methods for Quantification of Viral Load and Resistance to Antiretroviral Drugs in Patients Given Zidovudine Monotherapy

ABSTRACT Virological assays for human immunodeficiency virus type 1 load and drug resistance can broadly be divided into culture-based and molecular biology-based methods. Culture-based methods give a direct measure of infectious virus load and phenotypic drug resistance, whereas molecular biology-based methods are indirect, assaying nucleic acid levels to determine virus load and point mutations associated with drug resistance. We have compared culture-based and non-culture-based methods for patients enrolled in a placebo-controlled trial of zidovudine (the Concorde Trial). Virus loads were assayed by culture of peripheral blood mononuclear cells (PBMCs) or quantitative PCR, and drug resistance was assayed in culture or in a quantitative, PCR-based point mutation assay. The rates of detection of viremia and drug resistance were higher by PCR than by culture for this population of subjects. Comparison of the virus loads by the two measures showed a good correlation for virus loads in PBMCs but a poor correlation for virus loads in plasma. The latter result probably reflected the inaccuracies of culture in assaying plasma with the low infectious virus titers seen in the study population. The concordance of phenotypic and genotypic drug resistance methods was high, with all phenotypically resistant isolates having at least one resistance-associated mutation and with no mutations being found in a drug-sensitive isolate. Genomic resistance scores (weighted sums of levels of resistance mutations) showed good correlations with the levels of phenotypic resistance, and both resistance measures were observed to increase as the duration of exposure to drug increased. Overall, non-culture-based methods were shown to correlate well with culture-based methods and offer a low-cost, high-throughput alternative. However, culture-based methods remain the final arbiters of infectious virus load and phenotypic drug resistance and are unlikely to be superseded entirely.

[1]  K. Harada,et al.  Direct Observation of Vortex Dynamics in Superconducting Films with Regular Arrays of Defects , 1996, Science.

[2]  J. Darbyshire,et al.  Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals , 1996, The Lancet.

[3]  John W. Mellors,et al.  Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.

[4]  C. Loveday,et al.  HIV-1 RNA serum-load and resistant viral genotypes during early zidovudine therapy , 1995, The Lancet.

[5]  D. Ho,et al.  Clinical evaluation of branched DNA signal amplification for quantifying HIV type 1 in human plasma. , 1995, AIDS research and human retroviruses.

[6]  D. van Strijp,et al.  A one-tube quantitative HIV-1 RNA NASBA nucleic acid amplification assay using electrochemiluminescent (ECL) labelled probes. , 1994, Journal of virological methods.

[7]  Ann Marie Swart,et al.  Concorde: MRC/ANRS randomised double-blind controlled trial of immediate and deferred zidovudine in symptom-free HIV infection , 1994, The Lancet.

[8]  J. Sninsky,et al.  Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection , 1994, Journal of clinical microbiology.

[9]  B. Larder,et al.  Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates , 1994, Antimicrobial Agents and Chemotherapy.

[10]  J. Currier Zidovudine for asymptomatic human immunodeficiency virus infection , 1994, ACP Journal Club.

[11]  B. Larder,et al.  Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing , 1993, Nature.

[12]  J. Condra,et al.  Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors , 1993, Antimicrobial Agents and Chemotherapy.

[13]  S. Bloor,et al.  Variable relationship between proviral DNA load and infectious virus titre in the peripheral blood mononuclear cells of HIV‐1‐infected individuals , 1993, AIDS.

[14]  D. Katzenstein,et al.  Measurement of HIV virus load and genotypic resistance by gene amplification in asymptomatic subjects treated with combination therapy. , 1993, Journal of acquired immune deficiency syndromes.

[15]  S. J. Clark,et al.  High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. , 1993, Science.

[16]  C. Loveday,et al.  HIV-1 plasma viraemia quantification: a non-culture measurement needed for therapeutic trials. , 1993, Journal of virological methods.

[17]  C. Loveday,et al.  A microtitre format point mutation assay: Application to the detection of drug resistance in human immunodeficiency virus type‐1 infected patients treated with zidovudine , 1992, Journal of medical virology.

[18]  H. Mitsuya,et al.  Plasma HIV-1 viremia in HIV-1 infected individuals assessed by polymerase chain reaction. , 1992, AIDS research and human retroviruses.

[19]  F. Brun-Vézinet,et al.  HIV-1 sensitivity to zidovudine: a consensus culture technique validated by genotypic analysis of the reverse transcriptase. , 1992, Journal of virological methods.

[20]  B. Larder,et al.  Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[21]  S D Kemp,et al.  Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. , 1991, AIDS.

[22]  S W Lagakos,et al.  Zidovudine in Asymptomatic Human Immunodeficiency Virus Infection , 1990 .

[23]  P. Simmonds,et al.  Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers , 1990, Journal of virology.

[24]  D. Ho,et al.  Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. , 1989, The New England journal of medicine.

[25]  A. Collier,et al.  Plasma viremia in human immunodeficiency virus infection. , 1989, The New England journal of medicine.

[26]  S D Kemp,et al.  Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). , 1989, Science.

[27]  Andreas Meyerhans,et al.  Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations , 1989, Cell.

[28]  D. Katzenstein,et al.  Plasma viremia in human immunodeficiency virus infection: relationship to stage of disease and antiviral treatment. , 1992, Journal of acquired immune deficiency syndromes.

[29]  B. Larder,et al.  Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. , 1992, The Journal of infectious diseases.

[30]  M. Ascher,et al.  A multicenter proficiency trial of gene amplification (PCR) for the detection of HIV-1. , 1991, Journal of acquired immune deficiency syndromes.

[31]  R. Higuchi,et al.  Simple and Rapid Preparation of Samples for PCR , 1989 .